ClinicalTrials.gg
TerminatedNCT06268574RIVER-52Updated Sep 16, 2026

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

A Phase 2 interventional study of RVU120 in Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome, sponsored by Ryvu Therapeutics SA. Terminated at 41 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Ryvu Therapeutics SA · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Leukemia, Myeloid, Acute with a site in Poland — 14 open to participants now, 23 under way, 11 of them phase 3. Leukemia, Myeloid, Acute · Poland.

Enrollment
59th of 75
62 · median 255
Started
2024
with 4 others
Phase 2
17 of 76
4 open now
Registered
68th of 76
by date
Lead sponsor
4 of 76
Ryvu Therapeutics SA

Among the 76 studies in Leukemia, Myeloid, Acute with a site in Poland, this one is the 59th largest by enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2024, is one of 17 in phase 2, and was the 68th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

14 of the 76 studies in Leukemia, Myeloid, Acute with a site in Poland are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Leukemia, Myeloid, Acute with a site in Poland, or all of them as a file.
02

Study summary

The goal of this study is to assess the safety, tolerability, anti-tumor activity (efficacy), pharmacokinetics (PK), and pharmacodynamics (PD) of the agent RVU120 when administered to adult patients with relapsed or refractory acute myeloid leukemia (AML) or relapsed or progressing high-risk myelodysplastic syndrome (HR-MDS) and who have no alternative therapies available. The study consists of two parts. Part 1 will assess the safety and tolerability of the dosages given and the level of anti-tumor activity or clinical response. Based on the results from part 1 the study will continue to enrol patient into Part 2 which will continue to evaluate safety and tolerability and anti-tumor activity in a larger number of patients.

Read the detailed description

Patients entering the study will undergo a Screening Period of up to 21 days, a Treatment Period where they will take the drug every other day (7 times in 13 days) in cycles of 21 days, an End of Treatment period (lasting approximately 30 days after last dose), and a 1-year Follow-up Period where participants will be contacted every 3 months for progression and survival status. In Part 1, patients with AML or HR-MDS will be enrolled. All patients will receive RVU120 until the patient meets eligibility for transplant, until there is disease progression or if there are signs of intolerance. A patient may withdraw from the study at any time at their own request or may be withdrawn at any time at the discretion of the Investigator. Depending on the outcome of part 1, part 2 may include patients with HR-MDS and AML irrespective of NPM1 mutation status.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must sign a written document and complete study related procedures
  • Patients must have a diagnosis of AML or HR-MDS (per 2022 WHO classification) with MDS confirmed as high risk with IPSS-R
  • Patients must have AML (per ELN 2022 criteria)
  • Patients must have relapsed or progressing HR-MDS (per IWG response criteria)
  • Patients must have failed treatment and have no alternative therapeutic options likely to produce clinical benefit
  • Patients must have performance status of 0 to 2
  • Patients must have adequate end organ function defined as:

    1. WBC \< 30 x 10(9)/L on Day 1 prior to first dose of study drug
    2. count > 10,000/mcL on Day 1 prior to first dose of study drug
    3. Serum albumin ≥ 25 g/L (2.5 g/dL)
    4. Normal coagulation (elevated [INR], prothrombin time or activated partial thromboplastin time [APTT] \<1.3 x the [ULN] acceptable)
    5. (aspartate transaminase) and ALT (alanine transaminase) ≤ 3 x ULN (upper limit of normal)
    6. Total ≤ 3 x ULN
    7. (Cockcroft \& Gault formula) ≥ 30 mL/min

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system (CNS) leukemia.
  • Diagnosis of acute promyelocytic leukemia (APL), the M3 subtype of AML.
  • Previous treatment with CDK8 and/or CDK19-targeted therapy.
  • Major surgery within 28 days prior to first dose of study drug.
  • Hematopoietic stem cell transplant within 120 days prior to first dose of study drug.
  • Active, ≥Grade 2 acute (GVHD), active moderate-to-severe chronic GVHD, or requirement for systemic medications for GVHD
  • Evidence of ongoing and uncontrolled systemic bacterial, fungal, or viral infection and acute inflammatory conditions (including pancreatitis).
  • Known seropositivity or history of active viral infection with (HIV).
  • Ongoing significant liver disease
  • Impairment of gastrointestinal function or gastrointestinal disease
  • Ongoing drug-induced pneumonitis.
  • Concurrent participation in another clinical trial.
  • Taking any medications, herbal supplements, or other substances (including smoking) that may interfere with the metabolism of the study drug
  • Significant cardiac dysfunction defined as myocardial infarction within 12 months of first dose of study drug, (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, poorly controlled angina or (LVEF) \<40% as per echocardiography or multiple gated acquisition (MUGA) scan.
  • History of ventricular arrhythmia, or ≥470 ms (Bazett's formula).
  • Prior history of other than AML, unless the participant has been free of the disease for 5 years or more prior to Screening
  • Pregnant or breast-feeding.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    RVU120 single agent

    RVU120 oral capsules administered at dose of 250 mg every other day on Days 1-13 of each 21-day cycle of treatment.

    Drug: RVU120

Interventions

  • DrugRVU120

    Drug pages: SEL-120 · Romaciclib · Silevertinib

    RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

    Also known as: SEL120

06

What researchers measure

Primary outcomes

  1. Complete Remission (CR), with and without measurable residual disease (MRD)

    Rate of CR, CRh, or CRi

    Time frame: 12 months

Secondary outcomes

  1. Overall response rate

    Overall response rate including CR, CRh, CRi, MLFS, or PR in AML patients or CR, PR, or marrow CR HR-MDS patients

    Time frame: 12 months

  2. Duration of response

    Time from first response to hematologial replase or death

    Time frame: 12 months

  3. Progression-free survival

    Time from first treatment to the first occurrence of disease progression or death

    Time frame: 12 months

  4. Overall survival

    Time from first treatment to death

    Time frame: 12 months

  5. Incidence of Adverse Events (Safety and Tolerability)

    Number and grade of adverse events assessed by CTCAE v5.0

    Time frame: Up to 24 months

  6. Percentage of participants bridged to hematopoietic stem cell transplantation

    Number of hematopoietic stem cell transplantations following response

    Time frame: 12 months

  7. Maximum Plasma Concentration (Cmax)

    Assessment of the peak plasma concentration (Cmax)

    Time frame: 12 months

  8. Maximum Plasma Concentration (Tmax)

    Assessment of the time to peak plasma concentration (Tmax)

    Time frame: 12 months

  9. Area Under the Concentration Time-Curve (AUC)

    Assessed of the area under the plasma concentration versus time curve (AUC)

    Time frame: 12 months

  10. Impact of treatment on hematological malignancy patient-reported outcomes (HM-PRO)

    Assess changes in summary scores of the HM-PRO using a three point impact scale (Not at all, A little, A lot) and a three-point severity scale (Not at all, Mild, Severe)

    Time frame: Up to 12 months

  11. Impact of treatment on health-related quality of life (QOL-E)

    Assess changes in summary scores of the QOL-E questionnaires using a four point scale in order of impact or severity from better to worse outcome (eg, Never, Rarely, Sometimes, Often)

    Time frame: Up to 12 months

07

Study locations

41 sites
  • Centre Hospitalier Universitaire Grenoble Alpes
    La Tronche, France
  • Centre Hospitalier Le Mans
    Le Mans, France
  • Centre Hospitalier Universitaire de Lille (CHU Lille)
    Lille, France
  • Institut Paoli Calmettes (IPC)
    Marseille, France
  • Centre Hospitalier Universitaire (CHU) de Nice - Hopital L'Archet I
    Nice, France
  • Centre Hospitalier Universitaire de Nimes (CHU) - Institut de Cancerologie du Gard
    Nîmes, France
  • Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis
    Paris, France
  • UNICANCER - Centre Henri-Becquerel
    Rouen, France
  • Azienda Ospedaliero Universitaria Delle Marche
    Ancona, 60126, Italy
  • Univerisity of Bologna Policlinico Sant'Orsola
    Bologna, 40138, Italy
  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
    Brescia, 25123, Italy
  • Careggi University Hospital
    Florence, 50134, Italy
  • Ospedale Vito Fazzi Lecce
    Lecce, 73100, Italy
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
    Meldola, 47014, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, 20162, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
  • Azienda Ospedaliera Policlinico Universitario Tor Vergata
    Roma, 00133, Italy
  • Humanitas Mirasole S.p.A.
    Rozzano, 20089, Italy
  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
    Turin, 10126, Italy
  • MTZ Clinical Research
    Warsaw, Mazowieckie Województwo 02-172, Poland
  • Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
    Biała Podlaska, 21-500, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
    Gliwice, 44-102, Poland
  • Pratia Hematologia Sp. z o.o.
    Katowice, 40-519, Poland
  • Szpital Wojewodzki Im. Dr. Ludwika Rydygiera w Suwalkach
    Suwałki, 16-400, Poland
  • MICS Centrum Medyczne Toruń
    Torun, 87-100, Poland
  • Instytut Hematologii I Transfuzjologii
    Warsaw, 02-776, Poland
  • Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
    Warsaw, 04-141, Poland
  • Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
    Wałbrzych, 58-309, Poland
  • Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii
    Wroclaw, 53-439, Poland
  • Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.
    Zielona Góra, 65-046, Poland
  • Hospital de la Santa Creu i de Sant Pau
    Barcelona, Spain
  • Hospital del Mar
    Barcelona, Spain
  • Institut Catala d'Oncologia Hospitalet
    Barcelona, Spain
  • Complejo Hospitalario De Caceres - Hospital General San Pedro De Alcantara
    Cáceres, Spain
  • Hospital Universitario La Paz (HULP)
    Madrid, Spain
  • MD Anderson Cancer Center Madrid
    Madrid, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, Spain
  • Clinica Universidad de Navarra
    Pamplona, Spain
  • Virgen del Rocío University Hospital
    Seville, Spain
  • Hospital Universitario La Fe
    Valencia, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jun 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Feb 20, 2024
StartActual
Jan 23, 2024
Primary completionActual
Jun 30, 2025
CompletionActual
Sep 5, 2025
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06268574
Lead sponsor
Ryvu Therapeutics SA
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Jan 23, 2024
Primary completion
Jun 30, 2025
Completion
Sep 5, 2025
Last update
Sep 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SEL-120 · Romaciclib · Silevertinib

Start the discussion